留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌肝移植免疫抑制治疗中激素的撤离

李洋 陈规划

李洋, 陈规划. 肝癌肝移植免疫抑制治疗中激素的撤离[J]. 器官移植, 2014, 5(3): 149-151. doi: 10.3969/j.issn.1674-7445.2014.03.005
引用本文: 李洋, 陈规划. 肝癌肝移植免疫抑制治疗中激素的撤离[J]. 器官移植, 2014, 5(3): 149-151. doi: 10.3969/j.issn.1674-7445.2014.03.005

肝癌肝移植免疫抑制治疗中激素的撤离

doi: 10.3969/j.issn.1674-7445.2014.03.005
基金项目: 

国家十二五科技重大专项课题 2012ZX10002017-005

详细信息
    通讯作者:

    陈规划,Email:chgh1955@263.net

  • 中图分类号: R617

  • [1] Maddrey WC. Transplantation of the liver[M]. New York: Elsevier, 1988: 1-22.
    [2] Madrey WC, Sorrell MF. Transplantation of the Liver[M]. 2nd ed. Norwalk: Appleton and Lange, 1995: 225-245.
    [3] Margarit C, Martínez Ibañez V, Tormo R, et al. Maintenance immunosuppression without steroids in pediatric liver transplantation[J]. Transplant Proc,1989,21(1 Pt 2):2230-2231. http://cn.bing.com/academic/profile?id=2443370875&encoded=0&v=paper_preview&mkt=zh-cn
    [4] Yazawa H, Kato T, Nakada T, et al. Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell cytostasis[J]. Int J Cancer,1999,81(1):74-80. doi: 10.1002/(ISSN)1097-0215
    [5] Ho WL, Wu CC, Yeh DC, et al. Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma[J]. Surgery,2002,131(1):19-25. doi: 10.1067/msy.2002.118710
    [6] Miyagi S, Kawagishi N, Sekiguchi S, et al. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma[J]. Transplant Proc,2012,44(3):797-801. doi: 10.1016/j.transproceed.2012.01.012
    [7] Mazzaferro V, Rondinara GF, Rossi G, et al. Milan multicenter experience in liver transplantation for hepatocellular carcinoma[J]. Transplant Proc,1994,26(6):3557-3560. http://cn.bing.com/academic/profile?id=2404574882&encoded=0&v=paper_preview&mkt=zh-cn
    [8] Chen ZS, He F, Zeng FJ, et al. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol,2007,13(39):5273-5276. doi: 10.3748/wjg.v13.i39.5273
    [9] Xing T, Huang L, Yu Z, et al. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma[J]. PLoS One,2013,8(8):e71251. doi: 10.1371/journal.pone.0071251
    [10] Stegall MD, Everson GT, Schroter G, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss[J]. Hepatology,1997,25(1):173-177. doi: 10.1002/(ISSN)1527-3350
    [11] Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials[J]. Liver Transpl,2008,14(4):512-525. doi: 10.1002/(ISSN)1527-6473
    [12] Pekow JR, Bhan AK, Zheng H, et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis[J]. Cancer,2007,109(12):2490-2496. doi: 10.1002/(ISSN)1097-0142
    [13] Alsatie M, Kwo PY, Gingerich JR, et al. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C[J]. J Clin Gastroenterol,2007,41(4):416-421. doi: 10.1097/01.mcg.0000225593.93577.64
    [14] Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes[J]. Transpl Int,2009,22(9):892-905. doi: 10.1111/tri.2009.22.issue-9
    [15] Kato T, Yoshida H, Sadfar K, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study[J]. Transplant Proc,2005,37(2):1217-1219. doi: 10.1016/j.transproceed.2004.12.042
    [16] 高学松,成军,甄真,等.核孔复合体相互作用蛋白(NPIP)对乙型肝炎病毒核心启动子转录活性的调节作用[J].世界华人消化杂志,2004,12(10):2488-2491. http://www.cnki.com.cn/Article/CJFDTotal-XXHB200410069.htm

    Gao XS, Cheng J, Zhen Z, et al. Regulating effect of nuclear pore complex interaction proteins(NPIP) on transcriptional activity of core promoter of hepatitis B virus[J]. World Chin J Dig,2004,12(10):2488-2491. http://www.cnki.com.cn/Article/CJFDTotal-XXHB200410069.htm
    [17] Lupo L, Panzera P, TandoiF, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial[J]. Transplantation,2008,86(7):925-931. doi: 10.1097/TP.0b013e318186b8a3
    [18] Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage[J]. Liver Transpl,2004,10(6):728-733. doi: 10.1002/(ISSN)1527-6473
    [19] Figueras J, Prieto M, Bernardos A, et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts[J]. Transpl Int,2006,19(8):641-648. doi: 10.1111/tri.2006.19.issue-8
    [20] Reggiani P, Arru M, Regazzi M, et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation[J]. Transplant Proc,2005,37(4):1697-1699. doi: 10.1016/j.transproceed.2005.02.111
  • 加载中
计量
  • 文章访问数:  33
  • HTML全文浏览量:  61
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2014-05-15

目录

    /

    返回文章
    返回